These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 11585344)
21. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921 [TBL] [Abstract][Full Text] [Related]
22. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. Kaji H; Kanatani M; Sugimoto T; Chihara K Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780 [TBL] [Abstract][Full Text] [Related]
23. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985 [TBL] [Abstract][Full Text] [Related]
24. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. Michael H; Härkönen PL; Väänänen HK; Hentunen TA J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275 [TBL] [Abstract][Full Text] [Related]
25. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286 [TBL] [Abstract][Full Text] [Related]
27. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996 [TBL] [Abstract][Full Text] [Related]
28. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. Jimi E; Akiyama S; Tsurukai T; Okahashi N; Kobayashi K; Udagawa N; Nishihara T; Takahashi N; Suda T J Immunol; 1999 Jul; 163(1):434-42. PubMed ID: 10384146 [TBL] [Abstract][Full Text] [Related]
29. ADAM8: a novel osteoclast stimulating factor. Choi SJ; Han JH; Roodman GD J Bone Miner Res; 2001 May; 16(5):814-22. PubMed ID: 11341326 [TBL] [Abstract][Full Text] [Related]
30. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. Kondo H; Guo J; Bringhurst FR J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438 [TBL] [Abstract][Full Text] [Related]
31. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. Takasu H; Sugita A; Uchiyama Y; Katagiri N; Okazaki M; Ogata E; Ikeda K J Clin Invest; 2006 Feb; 116(2):528-35. PubMed ID: 16424941 [TBL] [Abstract][Full Text] [Related]
32. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. Mukohyama H; Ransjö M; Taniguchi H; Ohyama T; Lerner UH Biochem Biophys Res Commun; 2000 Apr; 271(1):158-63. PubMed ID: 10777696 [TBL] [Abstract][Full Text] [Related]
33. Role of TAFII-17, a VDR binding protein, in the increased osteoclast formation in Paget's Disease. Kurihara N; Reddy SV; Araki N; Ishizuka S; Ozono K; Cornish J; Cundy T; Singer FR; Roodman GD J Bone Miner Res; 2004 Jul; 19(7):1154-64. PubMed ID: 15176999 [TBL] [Abstract][Full Text] [Related]
34. Activation of protease-activated receptor-2 leads to inhibition of osteoclast differentiation. Smith R; Ransjö M; Tatarczuch L; Song SJ; Pagel C; Morrison JR; Pike RN; Mackie EJ J Bone Miner Res; 2004 Mar; 19(3):507-16. PubMed ID: 15040840 [TBL] [Abstract][Full Text] [Related]
36. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. Hofbauer LC; Khosla S; Dunstan CR; Lacey DL; Boyle WJ; Riggs BL J Bone Miner Res; 2000 Jan; 15(1):2-12. PubMed ID: 10646108 [TBL] [Abstract][Full Text] [Related]
37. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477 [TBL] [Abstract][Full Text] [Related]
38. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity. Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309 [TBL] [Abstract][Full Text] [Related]
39. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804 [TBL] [Abstract][Full Text] [Related]
40. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]